Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
|Title||Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.|
|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Sallee, FR, Lyne A, Wigal T, McGough JJ|
|Journal||Journal of child and adolescent psychopharmacology|
|Date Published||2009 Jun|
|Keywords||Adolescent, Adrenergic alpha-Agonists, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Guanfacine, Humans, Male, Treatment Outcome|
Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR.
|Alternate Journal||J Child Adolesc Psychopharmacol|